Company intelligence / Profile preview

Arquer Diagnostics

Sunderland, England, United Kingdomlabmate-online.com ↗

Ownership: Private
Employees: ~3
Development stage: Commercial

Overview

The company's lead product, ADXBLADDER, demonstrated high sensitivity and specificity in detecting bladder cancer using a non-invasive urine test. The technology can reportedly rule out bladder cancer within hours with up to 99% accuracy. Products for prostate and endometrial cancers were undergoing clinical validations as of early 2024.

Therapeutic areas: Oncology
Modalities: DeviceImmunoassay-based diagnostic test
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

ADX BLADDER

Commercial

Indications: Bladder cancer

Partnerships

NHS England/NHS hospitals used the product during COVID pandemic to clear diagnosis backlogs

Beyond the preview

Go deeper on Arquer Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arquer Diagnostics.

Explore the full profile